qinlock
deciphera pharmaceuticals (netherlands) b.v. - ripretinib - tumori stromali gastrointestinali - agenti antineoplastici - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agenti antineoplastici - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
uplizna
horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - immunosoppressori - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.
quviviq
idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - sleep initiation and maintenance disorders - psicolettici - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
cevenfacta
laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antiemorragici - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - agenti antineoplastici - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
opfolda
amicus therapeutics europe limited - miglustat - glicogen storage disease type ii - altri prodotti per il tratto alimentare e il metabolismo - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).
protertuss
prophinpharma s.p.a. - sedativi della tosse ed espettoranti - sedativi della tosse ed espettoranti
bronchised
hoechst pharma s.p.a. - sedativi della tosse ed espettoranti - sedativi della tosse ed espettoranti
pasticca rr
home products italiana s.p.a. - sedativi della tosse ed espettoranti - sedativi della tosse ed espettoranti